Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT00407303 is registered in ClinicalTrials.gov with Gemin X as lead sponsor.

NCT NCT00407303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00407303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Lead sponsor
Gemin X
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2006
Completion date
November 30, 2009
Enrollment
24 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

mantle-cell lymphoma